SI vs NVCR vs INVA vs ZBH vs SYK

For growth investors, SHOULDER INNOVATIONS, INC.

(SI) is the stronger pick with 64. 1% revenue growth year-over-year, versus 7. 2% for Zimmer Biomet Holdings, Inc. (ZBH). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate SHOULDER INNOVATIONS, INC. (SI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Stryker Corporation at 35. 1x. On forward P/E, Innoviva, Inc. is actually cheaper at 7. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 0. 70x versus Stryker Corporation's 1. 32x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +83. 8%, compared to -89. 8% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: SYK returned +186. 0% versus ZBH's -18. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 11β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 1787% more volatile than INVA relative to the S&P 500. On balance sheet safety, Innoviva, Inc. (INVA) carries a lower debt/equity ratio of 23% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), SHOULDER INNOVATIONS, INC.

(SI) is pulling ahead at 64. 1% versus 7. 2% for Zimmer Biomet Holdings, Inc. (ZBH). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -22. 2% for SHOULDER INNOVATIONS, INC.. Over a 3-year CAGR, SYK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -49. 4% for SHOULDER INNOVATIONS, INC. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -46. 3% for SI. At the gross margin level — before operating expenses — SI leads at 77. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 0. 70x versus Stryker Corporation's 1. 32x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Innoviva, Inc. (INVA) trades at 7. 3x forward P/E versus 19. 7x for Stryker Corporation — 12. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 83. 0% to $33. 50.

In this comparison, ZBH (1.

1% yield), SYK (1. 1% yield) pay a dividend. SI, NVCR, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 1% yield, +186. 0% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +186. 0%, NVCR: +51. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SI is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; ZBH is a mid-cap quality compounder stock; SYK is a mid-cap quality compounder stock. ZBH, SYK pay a dividend while SI, NVCR, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.